We were unable to classify the risk of BRAF and MEK cardiotoxicity according to the Heart Failure Association (HFA)-International Cardio-Oncology Society (ICOS) tool as the patient did not have echocardiography or cardiac markers examined before the start of treatment of the melanoma. The gene discussed is BRAF; the disease is heart failure.